Distinct extracellular matrix states uncouple collagen accumulation from pathological fibrosis in Duchenne muscular dystrophy

In the human body, muscle tissue is designed to contract and relax, a cycle of movement that relies on the delicate balance between repair and renewal. When muscle is injured, the body naturally sends in a crew of repair cells to clear away damage and lay down a temporary scaffold of proteins, known as the extracellular matrix, to hold everything together. In a healthy recovery, this scaffold is eventually remodeled and the muscle returns to its original strength. However, in certain chronic conditions, this repair process goes awry. Instead of fading away, the scaffolding builds up into thick, rigid scars that crowd out healthy muscle fibers. This condition, called fibrosis, is a major cause of disability in diseases where muscles are constantly breaking down, such as Duchenne muscular dystrophy. For decades, doctors and scientists have assumed that the severity of this scarring is directly tied to how much of this protein scaffold is present: more protein meant worse scarring. This belief has shaped how researchers measure disease progression and search for treatments, operating on the simple idea that if you can stop the protein from accumulating, you stop the disease.

A new study challenges this long-held assumption by looking closely at what happens inside the muscles of mice that model Duchenne muscular dystrophy. Researchers focused on a specific group of mice that had been genetically modified to produce extra amounts of a protective protein called sarcospan. These modified mice, known as mdxTG, show improved membrane integrity and muscle function compared to standard diseased mice, yet they behave very differently in one crucial way. While the standard mice develop severe, dense scars filled with immune cells, the modified mice accumulate even more of the protein scaffold, yet they lack these destructive, scar-like structures. Their muscles remain functional and lack the heavy, disorganized clumps of tissue that typically define the disease. This surprising observation led the team to ask a fundamental question: if there is more protein but less damage, then what exactly makes a scar pathological?

To answer this, the scientists examined the chemical makeup and physical arrangement of the protein scaffolds in both groups of mice. They found that while the amount of collagen, the main structural protein, was higher in the modified mice, the quality of that collagen was entirely different. In the standard mice, the protein formed a dense, chaotic web that trapped immune cells and created a rigid environment. In the modified mice, the protein was organized in a way that, while abundant, did not create the same hostile environment. When the researchers removed the muscle cells from both groups and placed healthy muscle cells onto the remaining scaffolds, the cells fared much better on the modified scaffold. They were protected from damage, whereas the cells on the standard scaffold suffered significant harm. This proved that the mere quantity of the protein was not the deciding factor; rather, the specific organization and biological activity of the matrix determined whether it acted as a protective support or a destructive scar.

The study also looked at the mechanical signals sent by these different environments. Both types of diseased muscle tissue were stiff, and this stiffness triggered a specific signal inside the cells of the body that build scar tissue. This signal, which involves a protein called YAP moving into the cell's control center, tells the cells to keep producing more collagen. The researchers found that this signal was active in both groups, even though only one group developed severe scarring. This suggests that while the mechanical stiffness drives the production of material, it is the way that material is arranged that dictates the final outcome. To test if they could stop this cycle, the team used a drug called verteporfin to block the YAP signal. In the mice, this treatment successfully reduced the production of collagen and lowered the amount of fibrosis, confirming that interrupting this specific signaling pathway could alter the disease process.

The findings extend beyond the mouse model. When the researchers examined muscle tissue from patients with Duchenne muscular dystrophy, they found that nuclear YAP was increased in the cells responsible for building scar tissue. This indicates that the mechanism observed in the mice is relevant to the human condition. The study concludes that counting the amount of collagen in a muscle is not enough to understand the severity of the disease. Two muscles can have similar amounts of protein but behave in completely opposite ways depending on how that protein is organized and how it communicates with the cells around it. By shifting the focus from simple quantity to the complex organization and activity of the tissue, this work offers a clearer path for understanding how to treat fibrosis, suggesting that therapies might need to target the quality and signaling of the scar tissue rather than just trying to reduce its volume.